Overview

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Status:
Completed

Trial end date:
2011-11-08

Target enrollment:

Participant gender:

Summary

MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Part 3 will determine a range of effective doses.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Trametinib